How to Get Tresiba (Insulin Degludec) in Kansas

What Is Tresiba and Why Kansas Prescribers Choose It

Tresiba is a basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours, making it the longest-acting commercially available insulin in the United States. Prescribers in Kansas select it when patients need a flatter pharmacokinetic profile than insulin glargine U-100 (Lantus) or insulin detemir (Levemir) can provide. The FDA approved insulin degludec in September 2015 for adults with type 1 and type 2 diabetes, and a pediatric indication for patients aged one year and older followed in 2019 [1].

The DEVOTE cardiovascular outcomes trial (N=7,637, 2-year follow-up) published in the New England Journal of Medicine showed insulin degludec was non-inferior to insulin glargine U-100 on a composite of major adverse cardiovascular events (MACE) in high-cardiovascular-risk patients with type 2 diabetes [2]. Severe hypoglycemia occurred at a rate of 0.83 episodes per patient-year with degludec versus 1.21 with glargine, a 40% reduction (P<0.001) that has direct implications for Kansas patients working in agriculture, operating machinery, or driving long rural distances [2].

The American Diabetes Association's 2024 Standards of Care classify basal insulins with demonstrated lower hypoglycemia rates as preferred options when cost is not prohibitive [3]. For Kansas patients at elevated hypoglycemia risk, that classification is directly relevant.

The FDA label specifies that Tresiba FlexTouch pens should be stored in the refrigerator (36°F to 46°F) before first use, then kept at room temperature (below 86°F) for up to 56 days after opening [1]. Kansas summers can push car interiors well above 86°F, so patients should never leave pens in a vehicle during warmer months.

Kansas Prescribing Authority: Who Can Write a Tresiba Prescription

Any licensed prescriber in Kansas with Schedule authority may write for Tresiba. That group includes medical doctors (MDs), doctors of osteopathic medicine (DOs), nurse practitioners (APRNs) with a collaborative practice agreement on file, and physician assistants (PAs) working within their supervising physician's scope. Kansas law (K.S.A. 65-1130) grants APRNs independent prescriptive authority in certain circumstances, though most collaborate under a written protocol [4].

Telehealth prescribing is fully permitted in Kansas under the Kansas Telehealth Act (K.S.A. 40-2,211), provided the prescriber establishes a valid patient-provider relationship, which Kansas defines as including a synchronous video visit [5]. A text-only or asynchronous portal message alone does not satisfy Kansas's relationship standard for a first-time controlled or non-controlled prescription.

Prescriptions for insulin degludec in Kansas must include the patient's name and date of birth, the drug name and concentration (e.g., 100 U/mL or 200 U/mL), the prescribed dose in units, the frequency, the quantity dispensed, and the prescriber's DEA or Kansas license number. Pharmacies in Kansas may dispense a 90-day supply when a prescriber authorizes refills.

Labs and Clinical Data Needed Before a Kansas Provider Prescribes Tresiba

Most Kansas clinicians will review a baseline hemoglobin A1c, a fasting glucose, a basic metabolic panel (BMP) to assess renal function, and a complete medication list before prescribing insulin degludec. Renal impairment does not require a dose adjustment for Tresiba, but the FDA label notes that glucose monitoring should be intensified in patients with renal or hepatic impairment because counter-regulatory responses may be blunted [1].

A recent A1c (within the past 90 days) satisfies most telehealth intake forms. If no recent lab work is available, several Kansas telehealth platforms partner with Labcorp or Quest Diagnostics draw sites to obtain a same-day or next-day A1c before a prescriber signs the order. LabCorp operates more than 30 patient service centers across Kansas, including locations in Wichita, Overland Park, Topeka, and Manhattan [6].

The HealthRX clinical team uses the following five-point intake checklist for new Tresiba patients in Kansas:

1. A1c drawn within 90 days (target context: is A1c above 7.0% on current regimen?)
2. Current basal insulin dose and titration history, if any
3. Frequency and severity of hypoglycemic episodes in the prior 30 days
4. Renal function: serum creatinine and eGFR from a BMP within 12 months
5. Current use of thiazolidinediones, which may potentiate fluid retention when combined with insulin

Bringing these five data points to a first telehealth visit typically reduces consultation time and allows same-visit prescribing rather than requiring a follow-up appointment.

How to Get a Tresiba Prescription via Telehealth in Kansas

Kansas permits synchronous video telehealth visits to establish a valid patient-provider relationship, making a fully remote prescription pathway legal and practical for most state residents. A rural patient in Garden City or Liberal can complete the entire process without driving to Wichita or Kansas City [5].

A standard telehealth pathway for Tresiba in Kansas looks like this: the patient schedules an online visit (often same-day or next-day), uploads current lab work and a medication list, completes a video consultation with a licensed Kansas prescriber, and receives an electronic prescription sent directly to their preferred Kansas pharmacy or mail-order pharmacy within hours of the visit. Most platforms confirm prescription receipt to the pharmacy within 24 hours [7].

The Endocrine Society's 2022 clinical practice guideline on diabetes technology states that "telehealth modalities can maintain or improve glycemic outcomes compared with usual in-person care" for patients who have access to reliable internet [8]. Kansas FCC data show that approximately 94% of Kansas households have access to fixed broadband at 25 Mbps or faster, making synchronous video visits feasible for the vast majority of the state's population [9].

For patients in rural counties without reliable broadband, phone-only visits may suffice under temporary Kansas telehealth flexibility provisions, though prescribers must document the specific technological barrier in the chart.

Transferring an Existing Tresiba Prescription to a Kansas Pharmacy

Patients moving to Kansas or switching pharmacies within the state can transfer non-controlled prescriptions, which includes Tresiba, between pharmacies directly. The receiving Kansas pharmacist calls or electronically contacts the originating pharmacy, and the transfer is typically completed the same day. Federal law and Kansas pharmacy regulations (K.A.R. 68-7-11) allow the transfer of remaining refills on a valid prescription without requiring a new visit to the prescriber [10].

If a patient relocates from another state and the prescriber is not licensed in Kansas, a new prescription from a Kansas-licensed provider will be required. A telehealth visit is often the fastest route in that situation, frequently resolving within one business day.

One practical note: some mail-order pharmacies licensed in multiple states can continue shipping Tresiba to a new Kansas address under the original prescription, provided Kansas is on the pharmacy's license list and the prescription still has active refills. Patients should confirm this with their mail-order pharmacy before assuming continuity.

503A Compounding Pharmacies and Insulin Degludec in Kansas

Kansas-licensed 503A pharmacies may compound insulin degludec for individual patients when a prescriber determines that a commercially available product does not meet a specific patient need. Common clinical rationales include an allergy or documented intolerance to a commercially available formulation excipient, a need for a concentration not commercially available, or a requirement for a preparation device not compatible with standard pens [11].

503A pharmacies operate under state board of pharmacy oversight and must compound from FDA-registered active pharmaceutical ingredients. The Kansas State Board of Pharmacy maintains a public list of licensed compounding pharmacies at pharmacy.ks.gov [12]. Patients and prescribers should verify that a pharmacy holds an active 503A designation and, ideally, has USP 797 accreditation before using a compounded insulin product.

Compounded insulin is not therapeutically equivalent to FDA-approved Tresiba and will not carry the same clinical trial data. The ADA's 2024 Standards of Care advise against routine substitution of compounded insulin for commercially approved products without a specific medical rationale [3].

Kansas Medicaid, Commercial Insurance, and Prior Authorization for Tresiba

Kansas Medicaid (KanCare) covers Tresiba for patients with type 1 diabetes across all three managed care organizations (Aetna Better Health, Sunflower Health Plan, United Healthcare Community Plan). For type 2 diabetes, Tresiba is not on the KanCare preferred drug list as of this publication, meaning type 2 patients enrolled in KanCare will generally need to use a preferred basal insulin (typically insulin glargine or NPH) first, or obtain a medical exception [13].

Commercial insurance plans in Kansas frequently require prior authorization (PA) for Tresiba because insulin glargine biosimilars are lower-cost alternatives on most formularies. A PA for Tresiba typically requires documentation of the following: a current A1c above the plan's threshold (often 7.0% or higher), a prescriber attestation that the patient has tried and failed or has a documented contraindication to a preferred formulary basal insulin, the prescribed dose and frequency, and ICD-10 diagnosis codes (E10.x for type 1, E11.x for type 2) [14].

The American Association of Clinical Endocrinology (AACE) 2023 diabetes management guidelines state that "insulin degludec is associated with significantly lower rates of nocturnal hypoglycemia compared with insulin glargine U-100, providing a clinically meaningful reason for formulary step-through exceptions" [15]. That language, when quoted directly in a PA letter, strengthens the clinical justification.

Novo Nordisk's Tresiba savings card reduces out-of-pocket costs to as low as $99 per month for eligible commercially insured patients. Patients without insurance may access Tresiba through Novo Nordisk's Patient Assistance Program (NovoCare) if household income meets program thresholds [16].

Kansas Pharmacies That Stock Tresiba and Delivery Timelines

Major pharmacy chains operating in Kansas, including CVS, Walgreens, Walmart, and Dillons Pharmacy (Kroger), stock Tresiba FlexTouch pens in both 100 U/mL and 200 U/mL concentrations at most larger locations. Smaller independent pharmacies in rural Kansas may need 24 to 48 hours to order the product from their distributor if it is not in regular stock.

Mail-order pharmacies, including Express Scripts, OptumRx, and CVS Caremark, typically ship a 90-day supply of Tresiba to any Kansas address. Standard shipping takes three to five business days; expedited shipping is usually available for an additional fee. Insulin is shipped in temperature-controlled packaging to protect against Kansas summer heat during transit [7].

A patient receiving a same-day telehealth prescription in Kansas can generally have Tresiba in hand within three to seven business days when accounting for prescription processing, any insurance verification, and pharmacy shipment. Local pharmacy fill at a chain location can reduce that timeline to 24 to 48 hours if the product is in stock and insurance is straightforward.

The FDA's medication guide for Tresiba instructs patients not to share FlexTouch pens with other people even if the needle is changed, due to risk of blood-borne pathogen transmission [1]. Kansas pharmacists are required by state law to counsel patients on this point at first fill.

Starting Dose, Titration, and Monitoring in Kansas Clinical Practice

The FDA-approved starting dose for insulin-naive adults with type 2 diabetes is 10 units subcutaneously once daily, then titrated based on fasting glucose targets [1]. For patients transferring from another basal insulin, a unit-to-unit conversion from insulin glargine U-100 is generally used, while patients converting from NPH insulin use a 20% dose reduction as a starting point per the label [1].

The DEVOTE trial's pre-specified analysis of fasting plasma glucose found that insulin degludec produced a mean fasting glucose of 128 mg/dL at 2 years compared with 136 mg/dL with insulin glargine (P<0.001), while using a similar total daily insulin dose [2]. That 8 mg/dL fasting glucose difference may appear modest in isolation but translates to a meaningful A1c difference over time for patients who titrate consistently.

The ADA recommends that patients initiating basal insulin perform fasting glucose self-monitoring at minimum every day during titration, with a target fasting glucose of 80 to 130 mg/dL for most non-pregnant adults [3]. Kansas telehealth platforms typically schedule a 2-week follow-up call or secure message after Tresiba initiation to review the patient's fasting glucose log and adjust the dose.

Hypoglycemia remains the primary safety concern with all basal insulins. A glucose reading below 70 mg/dL should be treated promptly with 15 grams of fast-acting carbohydrates per ADA guidelines, and readings below 54 mg/dL constitute clinically significant hypoglycemia requiring documentation and possible dose reduction [3]. Kansas patients who experience more than two hypoglycemic episodes per week on a stable Tresiba dose should contact their prescriber before the scheduled follow-up.

Drug Interactions and Special Populations in Kansas

Insulin degludec's hypoglycemic effect may be potentiated by GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide), SGLT-2 inhibitors (empagliflozin, dapagliflozin), and certain sulfonylureas [1]. Prescribers adding any of these agents to an existing Tresiba regimen should discuss a 10 to 20% proactive basal dose reduction with the patient.

Thiazolidinediones such as pioglitazone can cause fluid retention and increase the risk of heart failure when combined with insulin. The FDA label carries a specific warning about this combination, and Kansas prescribers are advised to monitor patients for signs of fluid retention when initiating pioglitazone in a patient already on Tresiba [1].

Pregnant patients in Kansas require individualized insulin therapy. Tresiba is classified as FDA Pregnancy Category B (now described under the 2015 labeling rule as insufficient human data), and most endocrinologists and maternal-fetal medicine specialists in Kansas prefer insulin detemir or NPH for pregnant patients due to a longer safety record in pregnancy [17]. Kansas telehealth platforms that prescribe Tresiba should screen all women of reproductive age for current or planned pregnancy before initiating therapy.

Pediatric patients aged one year and older may receive Tresiba per the 2019 FDA label update. A 26-week trial in pediatric patients (N=350) showed non-inferior glycemic control and a 35% lower rate of nocturnal hypoglycemia versus insulin detemir [18]. Kansas pediatric endocrinology practices in Wichita and Kansas City routinely prescribe Tresiba for pediatric type 1 diabetes management.

Cost Comparison: Tresiba vs. Competing Basal Insulins Available in Kansas

Without insurance, Tresiba FlexTouch pens (5 x 3 mL, 100 U/mL) carry a list price of approximately $530 per package at Kansas retail pharmacies. Insulin glargine U-100 (Lantus) lists at approximately $340 for a comparable supply, while biosimilar glargines (Semglee, Rezvoglar) can be found for $100 to $150 per package through GoodRx or Mark Cuban's Cost Plus Drugs platform [19].

Novo Nordisk's NovoCare program can reduce Tresiba cost to $0 per month for qualifying uninsured patients with incomes at or below 400% of the federal poverty level [16]. Kansas residents should apply at novonordisk-us.com/patient-support before paying out-of-pocket retail prices.

GoodRx coupons for Tresiba at Kansas pharmacies typically range from $340 to $480 depending on location and chain, offering modest savings for uninsured patients who do not qualify for the NovoCare program. The manufacturer savings card remains the strongest cost-reduction tool for commercially insured Kansas patients who pay a co-pay rather than meeting a deductible [16].